Rebate Reshuffle: Could Pharma Foot The Bill To Offset Higher Premiums?
Executive Summary
Bernstein Research analysts said CMS could charge pharmaceutical manufactures a fee to offset increases in insurance premiums anticipated from the elimination of rebates in a "win-win" move.
You may also be interested in...
PBMs Were On Capitol Hill, But Pharma Still Took Some Heat
Drug makers remained front and center during the Senate Finance Committee's third hearing on drug pricing, even though leaders from five pharmacy benefit managers were testifying.
PBMs Were On Capitol Hill, But Pharma Still Took Some Heat
Drug makers remained front and center during the Senate Finance Committee's third hearing on drug pricing, even though leaders from five pharmacy benefit managers were testifying.
CMS Offers Part D Plans Financial Backstop If Rebates Eliminated In 2020
But CMS also advises Medicare Part D plans to develop bids for the 2020 plan year that include rebates, since the final version of the HHS rule eliminating the anti-kickback safe harbor for rebates may not be released in time for the June 3 bid submission deadline.